Introduction
Wild type p53 is a short-lived protein with very low basal intracellular levels (Gannon et al., 1990; Oren et al., 1981; Reihaus et al., 1990) . Most mutated forms of the protein, however, display markedly increased intracellular levels which appear to be an essential feature of their transforming activity. The increase appears to result from prolongation of the protein's half-life rather than an increase in its rate of synthesis (Finlay et al., 1988) . It has been known for some time that the half-life of both wild type and some mutant forms of p53 is decreased by interaction with the papillomavirus E6 protein through a mechanism involving E6-stimulated polyubiquitination and subsequent ATP-dependent proteolysis via the 26S proteasome Medcalf and Millner, 1993; Schener, 1990 Schener, , 1992 Schener, , 1993 Schener, , 1994 Shkedy et al., 1994) . Based on these ®ndings, it has been proposed that normal p53 degradation also involves ATP-and polyubiquitin-dependent, proteasome-mediated proteolysis. This hypothesis is supported by an in vitro study in rabbit reticulocyte lysate , and in vivo data demonstrating accumulation of p53 in a mutant murine cell line displaying a temperaturesensitive defect in ubiquitination (Chowdary et al., 1994) . The speci®city of such temperature-sensitive ubiquitination mutants in de®ning proteolytic pathways, however, may be limited because they have also been used to demonstrate a ubiquitination requirement for lysosomal degradation of certain proteins (Gropper et al., 1991) .
Investigation of the role of ubiquitination and of the proteasome in the in vivo stability of both wild type and mutated p53 has proven dicult for several reasons. To date, inhibition of ubiquitination has only been accomplished using genetic approaches as described above and, until very recently, speci®c inhibitors of the protease activities contained within the proteasome have been lacking. The 20S proteasome is a multicatalytic protease complex comprising about 14 individual subunits Hough et al., 1987; Orlowski and Michaud, 1989; Rivett, 1989) . In eukaryotes, it assembles into a larger 26S complex which displays ATP-dependent breakdown of ubiquitinated proteins. Although believed to be the catalytic core of the 26S complex, isolated 20S proteasomes require neither ATP nor a polyubiquitination signal for proteolysis. The 20S proteasome has been shown to possess three distinct proteolytic activities, characterized as chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide hydrolyzing activities. Recently, the fermentation product lactacystin was shown to covalently bind to a distinct proteasome subunit, X/MB1, resulting in the irreversible inhibition of the chymotrypsin-like and trypsin-like activities of the proteasome, and the reversible inhibition of the peptidylglutamyl-peptide hydrolyzing activity (Fenteany et al., 1995) . At the same time, lactacystin has no eect on other proteases, including calpain, cathepsin B, papain, chymotrypsin and trypsin. Lactacystin is thus the most selective proteasome inhibitor presently known (Fenteany et al., 1995) . Using lactacystin and several other proteasome inhibitors, Maki et al. have recently shown that proteasome inhibition in vivo results in accumulation and stabilization of wild type p53 protein (Maki et al., 1996) Because the pathway responsible for the normal turn-over of wild type p53 in vivo is just now being elucidated, little is known of the mechanisms by which degradation of mutated forms of the protein becomes compromised. While examining the factors responsible for the increased stability of mutated p53 proteins, we previously identi®ed a class of drug known as benzoquinone ansamycins which decrease the half-life of mutated p53 proteins in a variety of human tumor cells (Blagosklonny et al., 1995) . This activity of benzoquinone ansamycins is dependent on the HSP90 interactive properties of these drugs, but not on the site of mutation in the p53 protein (Blagosklonny et al., 1995 (Blagosklonny et al., , 1996 . Further, the wild type protein is unaected by drug treatment. The resultant reduced half-life of the mutant protein is due to increased degradation and not decreased synthesis (Blagosklonny et al., 1995) .
In the present study, we have utilized lactacystin, and the less speci®c proteasome inhibitor N-acetyl-LeuLeu-Norleucinal (ALLN), to examine both the sensitivity of mutated p53 to proteasomal degradation, and the involvement of the proteasome in the ansamycin-stimulated degradation of mutated p53. Our ®ndings demonstrate that, while mutated p53 is resistant to proteasome-mediated hydrolysis under native conditions, ansamycin-stimulated destabilization of the mutated protein is proteasome-dependent. Concomitant with restoration of proteasome sensitivity, benzoquinone ansamycins also stimulate the polyubiquitination of mutated p53.
Results
Wild type, but not mutated, p53 protein steady-state level is increased in vivo following proteasome inhibition
The lung carcinoma cell line A549 and the breast carcinoma cell line MCF7 express wild type p53 protein (Blagosklonny et al., 1995) . We ®rst monitored the cellular level of wild type p53 in A549 and MCF7 cells exposed to lactacystin for 4 h. Western blotting of total cell lysate with an anti-p53 antibody ( Figure 1a , lanes 1 ± 4) revealed that lactacystin treatment caused an approximately threefold increase in wild type p53 protein in A549 cells and an approximately eightfold increase in p53 protein in MCF7 cells. Similar results were obtained in MCF7 cells following 2 h exposure to the less speci®c, but potent, proteasome inhibitor, ALLN (Figure 1b, compare lanes 1 and 3) . In contrast, the non-speci®c serine and cysteine protease inhibitors leupeptin (175 mg/ml) and PMSF (2 mM) were without eect (data not shown). Inhibition of lysosomal protease function with ammonium chloride (2 h exposure) also failed to cause accumulation of wild type p53 (Figure 1b, compare lanes 1 and 2) . In contrast, the steady-state level of mutated p53 in two human breast carcinoma cell lines (SKBr3 and MDA-MB-231) was not aected by either lysosome or proteasome inhibition (Figure 1c , compare lanes 1 and 3, Figure 1e , compare lanes 1 and 4, and data not shown).
The increase in steady-state level of wild type p53 following proteasome inhibition is due to protein stabilization
In order to determine whether p53 protein accumulation during proteasome inhibition was due to protein stabilization, we examined the eects on p53 of cotreatment with the protein synthesis inhibitor cycloheximide together with ALLN. After 2 h exposure to ALLN, MCF7 cells were treated with 100 mM cycloheximide (®nal concentration) for various times. Controls were treated with cycloheximide alone. Cellular p53 protein level was determined by Western blotting total cell lysate. As can be seen clearly in Figure 2a , the p53 level in control MCF7 cells declined rapidly following cycloheximide exposure, indicating a protein half-life of 15 ± 20 min. However, after exposure to ALLN, p53 protein level remained unchanged even after 6 h in the presence of cycloheximide. These ®ndings are consistent with the hypothesis that proteasome inhibition increases p53 protein by blocking its degradation. (Blagosklonny et al., 1995) . The half-life of mutated p53 in the breast carcinoma cell line MDA-MB-231 is nearly 35 h in untreated cells ((Delmolino et al., 1993) and Blagosklonny et al., unpublished observations) , but a 12 ± 16 h exposure of these cells to GA causes an approximate 50% reduction in the p53 steady state level, again due to induction of protein instability (Blagosklonny et al., 1995) . In order to determine whether this phenomenon is mediated by the proteasome and/or lysosomal proteases, we tested the ability of lactacystin, ALLN and ammonium chloride to block benzoquinone ansamycin-induced degradation of mutant p53. When SKBr3 cells were treated for 4 h with GA, lactacystin, or a combination of the two drugs, proteasome inhibition clearly reversed the eect of GA on the p53 steady state level ( Figure 1c , compare lanes 1, 2 and 4). Substitution of ALLN for lactacystin was similarly antagonistic to GA (Figure 1e , compare lanes 1, 2 and 5). Likewise, treatment of MDA cells with lactacystin for the initial 4 h of a 12 h exposure to GA completely blocked the reduction in p53 steady state level (Figure 1d ). In contrast, co-treatment of SKBr3 cells with ammonium chloride was unable to block GA-induced degradation of p53 ( Figure 1e) . As was the case with wild type p53, cycloheximide did not reverse the eects of proteasome inhibition on mutated p53 (see Figure 2b ).
The A1-5 rat ®broblast line markedly over-expresses a temperature-sensitive Val 135 p53 mutant which makes it particularly useful in examining p53 processing and turnover. When cells are maintained at 398C, both wild type and mutant conformations of the p53 molecule can be detected, but approximately 73% of the protein has been reported to be in a mutant conformation as determined by immunoprecipitation with epitope-speci®c monoclonal antibodies (Martinez et al., 1991) . Consistent with our ®ndings in human cell lines expressing mutant p53 proteins (Figure 1 4 to 3b, lanes 1 and 4) . This ®nding, along with the fact that chloroquine had no eect in combination with GA (compare lanes 2 and 6, Figure 3a and 3b) demonstrates that GA selectively stimulates transit of mutant p53 through a proteasome-dependent degradative pathway.
Ubiquitinated intermediates of mutated p53 can be detected following proteasome inhibition
In order to demonstrate GA-stimulated polyubiquitination of mutated p53, we made use of stably transfected A1-5 cells which strongly over-express a mutant p53 protein. Based on the ®ndings presented in Figure 3 , we examined both NP-40-soluble and -insoluble fractions from A1-5 cells treated with GA, lactacystin, or both drugs for 4 h at 398C. No higher molecular weight forms of p53 consistent with polyubiquitination were detected by Western blot in NP-40-soluble fractions from any treatment group (data not shown). In contrast, lactacystin treatment resulted in the detection of a ladder of higher molecular weight forms of p53 in the NP-40-insoluble fraction (Figure 4a, lane 3) . GA treatment alone did not produce such a ladder, but simultaneous treatment with GA and lactacystin resulted in even greater accumulation of higher molecular weight p53 forms (Figure 4a, lane 4) . Consistent with the hypothesis that these slower migrating forms might represent ubiquitinated p53 species, we found that GA resulted in a modest increase in total ubiquitinated proteins detected in the NP-40-insoluble fraction compared to control (Figure 4a , compare lanes 5 and 6). Treatment with lactacystin, on the other hand, resulted in a marked accumulation of ubiquitinated proteins as would be expected upon eective inhibition of proteasome activity (Figure 4a, lane 7) . Simultaneous treatment with both GA and lactacystin resulted in an even greater accumulation of ubiquitinated species ( Figure  4a , lane 8), suggesting that GA stimulates the ubiquitination of multiple proteins which then fail to be degraded when proteasome activity is inhibited.
In order to evaluate whether the higher molecular weight forms of p53 demonstrated in Figure 4a actually represent ubiquitinated species, we immunoprecipitated p53 from the NP-40-insoluble fraction of A1-5 lysates. The immunoprecipitates were analysed by SDS ± PAGE followed by Western blotting for p53 ( Figure 4b , lanes 1 ± 4). After probing for p53, the membrane was stripped by autoclaving and re-probed using an anti-ubiquitin anti-serum (Figure 4b , lanes 5 ± 8). Consistent with the ®ndings in Figure 4a , treatment with lactacystin resulted in the accumulation of a ladder of immunoprecipitable p53 species as did treatment with GA and lactacystin together. An increase in higher molecular weight forms following dual treatment was not evident in this experiment, probably for the technical reasons discussed below. Evidence that the ladder of p53-immunoreactive bands (Figure 4b , lanes 3 and 4) actually represents polyubiquitinated species is provided by reprobing the blot with anti-ubiquitin anti-serum. Treatment with lactacystin, or GA plus lactacystin, resulted in a ladder In order to be certain that the higher molecular size bands seen in Figure 4 are not a result of non-speci®c cross-reactivity, control immunoprecipitations using isotype-matched mouse IgG were performed, as well as immunoprecipitations from the p53-null cell line PC-3M. As seen in Figure 5a , p53 was detectable by Western blot as a band migrating slightly below the immunoglobulin heavy chain (IgG) only in precipitates from A1-5 cell lysate and only when p53-speci®c antibody was used for immunoprecipitation (compare Figure 5a , lane 2 to lanes 1, 3 and 4). As expected from the data in Figure 4 , a ladder of higher molecular size p53-immunoreactive bands is detected only in lysate prepared from A1-5 cells treated with GA and lactacystin. The detection of this ladder was dependent on the use of p53-speci®c antibody for immunoprecipitation (compare Figure 5a , lanes 5 and 6) and no ladder is detected in lysate of the p53-null cell line PC-3M (lanes 7 and 8). In order to con®rm that the ladder of bands seen in Figure 5a represents polyubiquitinated p53, the membrane was stripped by autoclaving and reprobed with rabbit anti-ubiquitin antiserum as in Figure 4 . A ladder of anti-ubiquitin-reactive bands is detected only in p53 immunoprecipitates prepared from drug-treated A1-5 cells (Figure 5b, lane 6) . The faint IgG bands seen in each lane result from slight crossreactivity of our goat anti-rabbit IgG secondary antibody with mouse IgG. Similar to the ®ndings in Figure 4 , the ladder of bands seen in Figure 5a is virtually superimposable over the ladder in Figure 5b . Again, the intensity of the bands is dramatically dierent in the two panels, but this ®nding is to be expected given the fact that mouse monoclonal versus rabbit polyclonal antibodies recognizing very dierent epitopes were used. In addition, it is likely that as ubiquitination of p53 increases, the anity of the antip53 antibody decreases, while the protein's reactivity with anti-ubiquitin antiserum increases. The apparent molecular sizes of each band in the ladder seen in Figure 5b (lane 6) were calculated based on the migration of known molecular size markers and are indicated to the right of the panel. With the exception of the 64 kDa band, the bands appear to increase in size as multiples of 7 kDa, as would be expected from progressive extension of a polyubiquitin chain. The nature of the 64 kDa band and the reason why no 74 kDa band is seen in the ladder are unclear at this time.
Discussion
In the present study, we have utilized lactacystin and the less speci®c inhibitor of proteasome activity, ALLN, to examine the processing of mutated p53 by the ubiquitin-proteasome system. Consistent with the recent ®ndings of Maki et al. (1996) , we found that inhibition of proteasome activity in tumor cells expressing wild type alleles resulted in a marked increase in cellular p53 levels ( Figure 1 ). As expected, this increase resulted from the stabilization of the protein in the presence of the proteasome inhibitor, not from its enhanced synthesis (Figure 2 ). Proteasome inhibition, however, had no eect on intracellular levels of mutated p53 in two human cell lines, indicating that transit through the normal degradative pathway utilized by wild type p53 is somehow compromised by mutations within the p53 protein. Such compromise is consistent with the elevated basal levels and prolonged intracellular half-lives characteristic of most mutated p53 species.
To begin to explore how degradation of mutated p53 is altered in tumor cells, we next examined the eects of GA, an HSP90 binding agent which has been shown previously to stimulate the proteasomemediated degradation of several cellular signaling proteins including receptor tyrosine kinases (Mimnaugh et al., 1996; Sepp-Lorenzino et al., 1995) and the glucocorticoid receptor (Whitesell and Cook, 1996) . We have previously reported that stable expression of the mutant, but not wild type, p53 conformation requires association of the p53 protein with the chaperone HSP90, and that by disturbing the association GA stimulates the degradation of mutant, but not wild type, p53 (Blagosklonny et al., 1995, . We now report that although proteasome inhibition does not aect the cellular level of mutated p53, GA-stimulated degradation of the mutant protein is sensitive to inhibition of the proteasome (Figure 1) . As was the case with the wild type protein, cycloheximide failed to reverse the eects of proteasome inhibition. Proteasomal degradation of proteins is classically dependent on the covalent attachment of multiple ubiquitin molecules to the target molecule. Although some evidence has been reported suggesting that the proteasome can degrade select non-ubiquitinated proteins eciently (Jariel-Encontre et al., 1995; Murakami et al., 1992) , most proteasomal degradation appears to be ubiquitin-dependent. Consequently, in order to con®rm that GA-stimulated degradation of mutant p53 is mediated by this system, we sought to identify polyubiquitinated p53 in GA-treated tumor cells. Although drug eects on cellular levels of mutant p53 could be reliably reproduced in human tumor cells, it was dicult to detect conjugated, higher molecular weight p53 following these experimental treatments. We and others have had diculty in demonstrating potential target protein-ubiquitin conjugates in vivo, probably because these conjugates are intermediates of degradation and as such are rare, unstable species (Maki et al., 1996; Mimnaugh et al., 1996; SeppLorenzino et al., 1995) . Even when they accumulate in the presence of proteasome inhibitors, such as lactacystin or ALLN, they remain subject to rapid de-ubiquitination by cellular hydrolases found in physical association with the proteasome complex (Eytan et al., 1993; Hadari et al., 1992) as well as elsewhere in the cytosol (Zhang et al., 1993) . These hydrolases are thought to release free ubiquitin from the proteolytic fragments generated by proteasome action, allowing this ubiquitin to be recycled for further use. Hydrolase activity would not be expected to be inhibited by lactacystin or ALLN based on the mechanism of action of these compounds (Fenteany et al., 1995; Ward et al., 1995) . As a result, in the presence of these drugs cellular p53 is not degraded but probably can still be de-ubiquitinated, as demonstrated in vitro by Shkedy et al. using reticulocyte lysate .
In order to overcome these diculties in demonstrating ubiquitinated p53, we made use of A1-5 ®broblasts stably over-expressing a murine p53 mutant protein. Due to the high level of over-expression of p53 in these cells, inhibition of proteasome action led to the accumulation of ubiquitinated p53 which was insoluble in non-ionic detergent, presumably due to protein denaturation and aggregation (Figure 3 ). This eect was clearly increased by co-treatment with GA suggesting stimulation of p53 ubiquitination by the drug. Accumulation of p53 in an insoluble form had two advantages in terms of identifying ubiquitinated intermediates. First, we were able to lyse cells in NP-40-containing buer and remove much of the hydrolase activity present in the cytosolic compartment while retaining p53 in a precipitated form which was resistant to hydrolase action. Second, partitioning of p53 from NP40-soluble to -insoluble fractions upon exposure to proteasome inhibitors in vivo allowed us to assess denaturation of p53 (presumably as a function of its ubiquitination) at the time of cell lysis even if subsequent manipulations (eg. resolubilization and immunoprecipitation) resulted in partial de-ubiquitination due to residual hydrolase activity.
When 100 mg of NP-40 insoluble material per lane (Figure 4a ) was analysed by Western blotting instead of 20 mg (Figure 3) , a clear ladder of higher molecular weight p53 forms was detectable. The bands increased in molecular weight as multiples of approximately 7 kDa, as would be expected for protein conjugates containing multiple ubiquitin molecules. The intensity of the bands was greatest in the material derived from cells treated simultaneously with GA and lactacystin consistent with stimulation of ubiquitination by GA. It is not clear at this time whether the immunoreactive p53 seen in the insoluble fraction under control conditions in the experiment pictured in Figure 4 (but not in Figure 3 where less material was analysed) represents contamination of the pellet with material from the soluble fraction, or whether some p53, because of its massive over-expression in these cells, exists in an aggregated form even under control conditions.
A ladder pattern of higher molecular weight p53 forms was also evident when p53 was immunoprecipitated from NP-40 insoluble material and then blotted with either an anti-p53 antibody or an anti-ubiquitin antiserum (Figure 4b ). The ®nding that the sizes of bands detected by the two dierent probes in this experiment are similar, and that the ubiquitin blot detects material immunoprecipitated from proteins resolubilized with SDS, provides very strong evidence that the bands actually represent polyubiquitinated p53 species. Cross-reactivity and/or non-speci®c adsorption is also ruled out by the lack of signal detectable in immunoprecipitates obtained using an isotype-matched control antibody, and by the lack of signal in precipitates from the p53-null cell line PC-3M ( Figure  5 ). In contrast to the pattern seen in Figure 4a , an increase in the intensity of the bands in dual drug treatment lanes is not evident in Figure 4b . This discrepancy probably results from either non-quantitative immunoprecipitation (antigen present in excess of precipitating antibody) or partial de-ubiquitination of some p53 during the immunoprecipitation procedure.
Inhibition of proteasome activity did not lead to increased cellular levels of mutant p53 in the human tumor cell lines examined (Figure 1 ). In A1-5 cells, however, lactacystin treatment did lead to accumulation of some p53 in an NP-40-insoluble form even when cells were maintained at the mutant conformation-permissive temperature of 398C, suggesting that ongoing ubiquitination and proteasomal degradation of mutant p53 occurs spontaneously in A1-5 cells. This disparity between our ®ndings with the human cell lines expressing mutant p53 and A1-5 cells can be explained in at least two non-mutually exclusive ways. First, up to 27% of the p53 in A1-5 cells maintained at 398C has been reported to exist in wild type conformation using epitope-speci®c antibodies (Martinez et al., 1991) . This material is presumably subject to ubiquitination and could accumulate in the presence of proteasome inhibitors. Second, although ubiquitination of wild type p53 may be much more ecient than that of mutant p53 in vivo, some ubiquitination of mutant p53 may occur at a low level, becoming detectable only when the mutant protein is greatly over-expressed, as Figure 1 for this purpose, and we have used A1-5 cells simply as an in vivo model in which to demonstrate clearly the intermediates involved in the ubiquitinproteasome pathway. In summary, the ®ndings presented here con®rm earlier studies that cellular levels of wild type p53 are regulated via ubiquitination and proteasome-mediated degradation in vivo (Maki et al., 1996) . While normal processing through this pathway appears to be impaired by mutations within the p53 protein which are associated with acquisition of transforming activity (Finlay et al., 1988) , we have demonstrated the feasibility of pharmacologically re-sensitizing mutated p53 proteins to proteasomal degradation. Most human tumors are heterozygous for p53 mutation and continue to express wild type protein from their normal allele. It has been proposed that the accumulation of mutated p53 may interfere with the function of this wild type protein in a dominant negative fashion through the formation of non-functional hetercomplexes between mutant and wild type species (Hinds et al., 1989; . Although much obviously remains to be learned, selective destabilization of mutant p53 protein in heterozygous tumors might allow for the restoration of endogenous wild type p53 function and potentially prove of therapeutic bene®t.
Materials and methods

Cell lines, cell culture, and reagents
Cell lines (A1-5, SKBr3, MDA-MB-231, A549, and MCF7) were cultured in an atmosphere of 6% CO 2 in air in DMEM media, supplemented with 10% heat-inactivated fetal bovine serum. A1-5 rat ®broblasts which markedly over-express a temperature-sensitive mutant murine p53 gene were obtained from J Martinez (Arizona Cancer Center, Tucson, AZ) and have been previously described (Martinez et al., 1991) . The cell line PC-3M, a metastatic variant of the prostate cancer cell line PC-3, was obtained from the Developmental Therapeutics Program, National Cancer Institute and cultured in RPMI 1640 with 10% heat-inactivated fetal bovine serum. All other cells were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in either 75 cm 2 asks or 10 cm diameter dishes and passaged when approximately 70% con¯uent. The benzoquinone ansamycin, geldanamycin (GA), was obtained gratis from the Drug Synthesis and Chemistry Branch, National Cancer Institute. It was prepared as a 10 mM stock solution in dimethylsulfoxide, and kept protected from light and frozen at 7208C. GA was diluted to 1 or 2 mM in complete medium for treatment of cells.
Lactacystin was purchased from Dr EJ Corey (Harvard University). A 2 mM stock solution was prepared in distilled water and kept at 48C. Unless otherwise stated, it was diluted in 10 mM in complete medium for treatment of cells. N-acetylLeu-Leu-Norleucinal (ALLN), ammonium chloride, and chloroquine were purchased from Sigma and freshly prepared in PBS (ALLN) or distilled water (ammonium chloride, chloroquine) before use. ALLN and chloroquine were used at 100 mM ®nal concentration, and ammonium chloride was used at a ®nal concentration of 2.5 mM. Unless otherwise stated, all other chemical reagents were purchased from Sigma.
Determination of p53 steady state levels
Steady state p53 levels were determined by Western blotting of total cell lysate with the monoclonal antibody pAb 421 (Oncogene Science) as previously described (Blagosklonny et al., 1995) . Cells were washed in phosphate-buered saline (PBS) and lysed in TNES buffer (50 mM Tris pH 7.5, 2 mM EDTA, 100 mM NaCl, 1% NP40, 20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mM PMSF). Lysates were cleared by centrifugation at 14 000 g for 15 min at 48C and equal amounts of protein from the NP-40-soluble supernatant were electrophoresed through 10% polyacrylamide gels (10% PAGE), and transferred to nitrocellulose by electroblotting. Blots were developed by incubation with a peroxidase-labeled secondary anti-mouse antibody followed by chemiluminescent peroxidase substrate (Dupont). p53 band intensity was quantitated by computerized densitometry using image analysis software (NIH Image). Several exposure times were quanti®ed to verify the dierences in band intensities observed.
Determination of polyubiquitinated p53
Following lysis in TNES buer, p53 protein was immunoprecipitated with monoclonal antibody PAb 421 (Oncogene Science) and protein A-Sepharose, electrophoresed, and transferred to nitrocellulose as above. For experiments evaluating p53 levels and ubiquitination in A1-5 cells, initial lysates were prepared in TNES as described above followed by removal of the NP-40-soluble supernatant for immunoprecipitation, and lysis of the remaining insoluble pellet for 15 mins in boiling TNES containing 2% SDS. These SDS lysates were then diluted 1 : 20 in TNES prior to immunoprecipitation in standard fashion. After fractionation of immunoprecipitates by SDS ± PAGE and transfer to nitrocellulose, membranes were autoclaved in water for 20 min to insure complete denaturation of ubiquitinated proteins, and then developed with a rabbit polyclonal anti-ubiquitin antiserum (1 : 400, Sigma) as described in the previous section. In some cases, polyubiquitinated proteins were analysed in total cell lysate by Western blotting following transfer to nitrocellulose. As a control for the presence of p53 protein in the ubiquitination experiments, p53-null PC-3M cells were treated identically to A1-5 cells.
